Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NYSE:BHVN NASDAQ:JANX NYSE:MBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$12.27+1.5%$9.08$5.51▼$12.48$1.59B1.232.79 million shs2.26 million shsBHVNBiohaven$15.70+10.3%$14.50$12.79▼$55.70$1.51B0.982.04 million shs2.81 million shsJANXJanux Therapeutics$25.11+0.6%$24.61$21.97▼$71.71$1.50B2.86895,949 shs527,337 shsMBXMBX Biosciences$14.72+11.4%$12.21$4.81▼$27.50$494.50MN/A329,571 shs577,730 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+1.49%+7.92%+38.64%+49.82%+119.50%BHVNBiohaven+10.56%+6.65%+17.57%-2.30%-58.79%JANXJanux Therapeutics+0.56%+9.99%-7.00%+3.42%-37.49%MBXMBX Biosciences+11.43%+21.05%+18.42%+31.90%+1,471,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.8348 of 5 stars1.53.00.00.02.92.53.1BHVNBiohaven3.7968 of 5 stars4.53.00.00.02.82.50.6JANXJanux Therapeutics2.3871 of 5 stars3.53.00.00.02.31.70.0MBXMBX Biosciences2.577 of 5 stars3.50.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$12.00-2.20% DownsideBHVNBiohaven 3.07Buy$53.75242.36% UpsideJANXJanux Therapeutics 3.08Buy$91.89265.95% UpsideMBXMBX Biosciences 3.00Buy$37.75156.45% UpsideCurrent Analyst Ratings BreakdownLatest MBX, BHVN, AUPH, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025MBXMBX BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$36.008/12/2025BHVNBiohavenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $30.008/12/2025BHVNBiohavenLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $50.008/12/2025BHVNBiohavenMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$63.00 ➝ $54.008/12/2025BHVNBiohavenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$57.00 ➝ $52.008/12/2025BHVNBiohavenBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $49.008/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.008/1/2025AUPHAurinia PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $9.007/30/2025AUPHAurinia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$17.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/11/2025JANXJanux TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.00(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$260.11M6.21$0.31 per share39.20$2.55 per share4.81BHVNBiohavenN/AN/AN/AN/A$1.27 per shareN/AJANXJanux Therapeutics$10.59M142.48N/AN/A$16.48 per share1.52MBXMBX BiosciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.4328.5421.91N/A23.31%20.06%13.81%N/ABHVNBiohaven-$846.42M-$7.66N/AN/AN/AN/A-270.65%-143.70%N/AJANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%N/AMBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/ALatest MBX, BHVN, AUPH, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2025BHVNBiohaven-$1.94-$1.94N/A-$1.94$0.41 millionN/A8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A7/31/2025Q2 2025AUPHAurinia Pharmaceuticals$0.17$0.16-$0.01$0.16$64.27 million$70.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.185.234.63BHVNBiohaven1.913.822.33JANXJanux TherapeuticsN/A47.0347.03MBXMBX BiosciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%BHVNBiohaven88.78%JANXJanux Therapeutics75.39%MBXMBX BiosciencesN/AInsider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%BHVNBiohaven16.00%JANXJanux Therapeutics8.10%MBXMBX Biosciences52.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300131.63 million115.57 millionOptionableBHVNBiohaven239105.79 million88.86 millionOptionableJANXJanux Therapeutics3060.09 million55.23 millionOptionableMBXMBX Biosciences3633.59 millionN/AN/AMBX, BHVN, AUPH, and JANX HeadlinesRecent News About These CompaniesHead-To-Head Survey: MBX Biosciences (MBX) versus Its Competitors1 hour ago | americanbankingnews.comA Glimpse of MBX Biosciences's Earnings PotentialAugust 14 at 11:19 AM | benzinga.comMBX Biosciences, Inc. (NYSE:MBX) Given Consensus Recommendation of "Buy" by AnalystsAugust 14 at 2:27 AM | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 13 at 2:29 AM | americanbankingnews.comMBX Biosciences Reports Progress and Financial StabilityAugust 11, 2025 | tipranks.comMBX Biosciences (NYSE:MBX) Earns Outperform Rating from Analysts at MizuhoAugust 8, 2025 | americanbankingnews.comMBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 7, 2025 | globenewswire.comMBX Biosciences (NYSE:MBX) Coverage Initiated at MizuhoAugust 6, 2025 | marketbeat.comMizuho Initiates Coverage of MBX Biosciences (MBX) with Outperform RecommendationAugust 5, 2025 | msn.comTD Asset Management Inc Raises Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)August 5, 2025 | marketbeat.comMBX Biosciences Inc. (MBX) Stock Price Today - WSJAugust 2, 2025 | wsj.comMBX Biosciences (NYSE:MBX) Shares Up 15.7% - What's Next?July 26, 2025 | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Receives Average Rating of "Buy" from AnalystsJuly 19, 2025 | marketbeat.comOppenheimer Initiates Coverage of MBX Biosciences (MBX) with Outperform RecommendationJuly 17, 2025 | msn.comOppenheimer Initiates Coverage on MBX Biosciences (NYSE:MBX)July 16, 2025 | marketbeat.comMBX Biosciences Inc Executives - MorningstarJune 25, 2025 | morningstar.comMMBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development - MorningstarJune 24, 2025 | morningstar.comMMBX Biosciences Inc Chart - MorningstarJune 24, 2025 | morningstar.comMMBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical DevelopmentJune 23, 2025 | globenewswire.comMBX Biosciences Submits IND for Obesity TreatmentJune 16, 2025 | tipranks.comMBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of ObesityJune 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBX, BHVN, AUPH, and JANX Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$12.27 +0.18 (+1.49%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$12.36 +0.10 (+0.77%) As of 08/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Biohaven NYSE:BHVN$15.70 +1.47 (+10.33%) Closing price 08/15/2025 03:58 PM EasternExtended Trading$15.55 -0.15 (-0.96%) As of 08/15/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Janux Therapeutics NASDAQ:JANX$25.11 +0.14 (+0.56%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$25.12 +0.02 (+0.06%) As of 08/15/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.MBX Biosciences NYSE:MBX$14.72 +1.51 (+11.43%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$14.50 -0.23 (-1.53%) As of 08/15/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Arista Networks: Cashing In as the Tollbooth for AI Traffic Green Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.